Angiogenic biomarkers for prediction of maternal and neonatal complications in suspected preeclampsia

References

• WHO. World Health Report: Make every mother and child count. Geneva Sibai 2005.
   Google Scholar
• Sibai BM. Eclampsia. VI. Maternal-perinatal outcome in 254 consecutive cases. Am J Obstet Gynecol 1990;163:1049–54; discussion 1054.
   PubMed Web of Science ®Google Scholar
• Schiff E, Friedman SA, Kao L, Sibai BM. The importance of urinary protein excretion during conservative management of severe preeclampsia. Am J Obstet Gynecol 1996;175:1313–1316.
   PubMed Web of Science ®Google Scholar
• Menzies J, Magee LA, Macnab YC, Ansermino JM, Li J, Douglas MJ, Gruslin A, et al. Current CHS and NHBPEP criteria for severe preeclampsia do not uniformly predict adverse maternal or perinatal outcomes. Hypertens Pregnancy 2007;26:447–462.
   PubMed Web of Science ®Google Scholar
• Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649–658.
   PubMed Web of Science ®Google Scholar
• Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006;12:642–649.
   PubMed Web of Science ®Google Scholar
• Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672–683.
   PubMed Web of Science ®Google Scholar
• Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, et al.; CPEP Study Group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006;355:992–1005.
   PubMed Web of Science ®Google Scholar
• Kleinrouweler CE, Wiegerinck MM, Ris-Stalpers C, Bossuyt PM, van der Post JA, von Dadelszen P, Mol BW, Pajkrt E. Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis. Br J Obstet Gynaecol 2012;119(7):778–87.
   Google Scholar
• Sibai BM, Lindheimer M, Hauth J, Caritis S, VanDorsten P, Klebanoff M, MacPherson C, et al. Risk factors for preeclampsia, abruptio placentae, and adverse neonatal outcomes among women with chronic hypertension. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 1998;339:667–671.
   PubMed Web of Science ®Google Scholar
• ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 2002;77:67–75.
   PubMed Web of Science ®Google Scholar
• Maynard SE, Moore Simas TA, Bur L, Crawford SL, Solitro MJ, Meyer BA. Soluble endoglin for the prediction of preeclampsia in a high risk cohort. Hypertens Pregnancy 2010;29:330–341.
   PubMed Web of Science ®Google Scholar
• Maynard SE, Moore Simas TA, Solitro MJ, Rajan A, Crawford S, Soderland P, Meyer BA. Circulating angiogenic factors in singleton vs multiple-gestation pregnancies. Am J Obstet Gynecol 2008;198(2):200.e1–7.
   Google Scholar
• Bdolah Y, Lam C, Rajakumar A, et al. Twin pregnancy and the risk of preeclampsia: bigger placenta or relative ischemia? Am J Obstet Gynecol 2008;198:428, e421–426.
   Google Scholar
• Erez O, Romero R, Espinoza J, Fu W, Todem D, Kusanovic JP, Gotsch F, et al. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med 2008;21:279–287.
   PubMed Web of Science ®Google Scholar
• Kusanovic JP, Romero R, Chaiworapongsa T, Erez O, Mittal P, Vaisbuch E, Mazaki-Tovi S, et al. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med 2009;22:1021–1038.
   PubMed Web of Science ®Google Scholar
• Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, Kusanovic JP, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008;21:9–23.
   PubMed Web of Science ®Google Scholar
• Mijal RS, Holzman CB, Rana S, Karumanchi SA, Wang J, Sikorskii A. Mid-pregnancy levels of angiogenic markers as indicators of pathways to preterm delivery. J Matern Fetal Neonatal Med 2012;25(7):1135–41.
   PubMedGoogle Scholar
• Wang A, Holston AM, Yu KF, Zhang J, Toporsian M, Karumanchi SA, Levine RJ. Circulating anti-angiogenic factors during hypertensive pregnancy and increased risk of respiratory distress syndrome in preterm neonates. J Matern Fetal Neonatal Med 2012; 25(8):1447–52.
   PubMedGoogle Scholar
• Young B, Levine RJ, Salahuddin S, Qian C, Lim KH, Karumanchi SA, Rana S. The use of angiogenic biomarkers to differentiate non-HELLP related thrombocytopenia from HELLP syndrome. J Matern Fetal Neonatal Med 2010;23:366–370.
   PubMed Web of Science ®Google Scholar
• Srinivas SK, Larkin J, Sammel MD, Appleby D, Bastek J, Andrela CM, Ofori E, Elovitz MA. The use of angiogenic factors in discriminating preeclampsia: are they ready for prime time? J Matern Fetal Neonatal Med 2010;23:1294–1300.
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Savasan ZA, Kusanovic JP, Ogge G, Soto E, Dong Z, et al. Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia. J Matern Fetal Neonatal Med 2011;24:1187–1207.
   PubMed Web of Science ®Google Scholar
• Rana S, Hacker MR, Modest AM, Salahuddin S, Lim KH, Verlohren S, Perschel FH, Karumanchi SA. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012;125(7):911–9.
   PubMedGoogle Scholar
• von Dadelszen P, Payne B, Li J, Ansermino JM, Broughton Pipkin F, Côté AM, Douglas MJ, et al.; PIERS Study Group. Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet 2011;377:219–227.
   PubMed Web of Science ®Google Scholar
• Reddy UM, Bettegowda VR, Dias T, Yamada-Kushnir T, Ko CW, Willinger M. Term pregnancy: a period of heterogeneous risk for infant mortality. Obstet Gynecol 2011;117:1279–1287.
   PubMed Web of Science ®Google Scholar
• Fleischman AR, Oinuma M, Clark SL. Rethinking the definition of “term pregnancy”. Obstet Gynecol 2010;116:136–139.
   PubMed Web of Science ®Google Scholar
• Ganzevoort W, Rep A, de Vries JI, Bonsel GJ, Wolf H; PETRA-investigators. Prediction of maternal complications and adverse infant outcome at admission for temporizing management of early-onset severe hypertensive disorders of pregnancy. Am J Obstet Gynecol 2006;195:495–503.
   PubMed Web of Science ®Google Scholar
• Martin JN Jr, Rinehart BK, May WL, Magann EF, Terrone DA, Blake PG. The spectrum of severe preeclampsia: comparative analysis by HELLP (hemolysis, elevated liver enzyme levels, and low platelet count) syndrome classification. Am J Obstet Gynecol 1999;180:1373–1384.
   PubMed Web of Science ®Google Scholar
• Sibai BM, Stella CL. Diagnosis and management of atypical preeclampsia-eclampsia. Am J Obstet Gynecol 2009;200:e481–487.
   PubMedGoogle Scholar
• Stella CL, Sibai BM. Preeclampsia: diagnosis and management of the atypical presentation. J Matern Fetal Neonatal Med 2006;19:381–386.
   PubMed Web of Science ®Google Scholar